Rituxan eases arthritis pain
From Times Staff and Wire Reports
Genentech Inc. and Biogen Idec Inc.’s Rituxan helped ease joint pain and inflammation in patients with persistent symptoms of rheumatoid arthritis that required more than one course of treatment, a study found.
The research showed that patients who underwent a second treatment with Rituxan six months after an initial dose had a statistically significant improvement in symptoms compared with those given a placebo the second time.
Genentech, based in South San Francisco, is seeking to expand its current U.S. approval for Rituxan.
